Literature DB >> 3965392

Suppression of in vitro lymphocyte proliferation in C57BL/10 ScN mice vaccinated with phase I Coxiella burnetii.

T A Damrow, J C Williams, D M Waag.   

Abstract

The effect of inactivated phase I and phase II Coxiella burnetii whole cell vaccine (WCV) on the response of murine spleen cells to mitogenic and antigenic stimuli was evaluated in C57BL/10 ScN endotoxin nonresponder mice with an in vitro lymphocyte proliferation assay. Intraperitoneal injection of phase I WCV into mice resulted in marked and persistent suppression of the proliferative response of spleen cells to concanavalin A, phytohemagglutinin, and pokeweed mitogen. This response was time and dose dependent and was not associated with decreased lymphocyte viability. By using a standard dose of 100 micrograms of phase I WCV, suppression of mitogenic responsiveness was first detected 3 days postinjection, attained maximum levels by day 14, and persisted for longer than 5 weeks. Suppression of mitogenic lymphocyte proliferation also was demonstrated after inoculation of animals with viable phase I organisms. The observed hyporesponsiveness of spleen cells from phase I WCV-injected animals was not either the result of a shift in the mitogenic dose optimum or due to a change in the day of in vitro peak response. Spleen cells from phase I WCV-injected mice were negatively regulated with homologous antigen. Investigation of the mechanism of action of phase I WCV, with a 51Cr-release assay, and trypan blue dye exclusion showed that phase I WCV was not directly cytolytic or cytotoxic to spleen cells from normal or vaccinated mice. Phase II WCV did not induce significant mitogenic hyporesponsiveness or negative modulation of spleen cells. These findings extend the observations of adverse host responses associated with the phase I WCV and underscore the need to develop a microbial fraction which possesses protective potency but which lacks the propensity to induce deleterious tissue reactions and immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965392      PMCID: PMC261490          DOI: 10.1128/iai.47.1.149-156.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  CYTOTOXIC TEST FOR DEMONSTRATION OF MOUSE ANTIBODY.

Authors:  E A BOYSE; L J OLD; I CHOUROULINKOV
Journal:  Methods Med Res       Date:  1964

2.  Immune responses in vitro. X. Functions of macrophages.

Authors:  C W Pierce; J A Kapp; D D Wood; B Benacerraf
Journal:  J Immunol       Date:  1974-03       Impact factor: 5.422

3.  Requirement for adherent cells in the primary and secondary immune response in vitro.

Authors:  O Sjöberg; J Andersson; G Möller
Journal:  Eur J Immunol       Date:  1972-04       Impact factor: 5.532

4.  Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine.

Authors:  R A Kishimoto; J W Johnson; R H Kenyon; M S Ascher; E W Larson; C E Pedersen
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

5.  Impaired lymphocyte function in untreated Hodgkin's disease.

Authors:  R Levy; H S Kaplan
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

6.  Suppression of in vitro antigen-induced lymphocyte transformation by carrageenan, a macrophage-toxic agent.

Authors:  W W Lake; D Bice; H J Schwartz; J Salvaggio
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

7.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

8.  Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum.

Authors:  H Kirchner; H T Holden
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

9.  Suppression of cellular immune responses in guinea pigs infected with spotted fever group rickettsiae.

Authors:  C N Oster; R H Kenyon; C E Pedersen
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

10.  Inhibition by Coxiella burnetii of ascites tumour formation in mice.

Authors:  J Kazár; S Schramek
Journal:  Acta Virol       Date:  1979-05       Impact factor: 1.162

View more
  8 in total

Review 1.  Animal models of Q fever (Coxiella burnetii).

Authors:  Kevin R Bewley
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

2.  A heat shock operon in Coxiella burnetti produces a major antigen homologous to a protein in both mycobacteria and Escherichia coli.

Authors:  M H Vodkin; J C Williams
Journal:  J Bacteriol       Date:  1988-03       Impact factor: 3.490

3.  Rocky Mountain spotted fever following cardiac transplantation.

Authors:  T M Rallis; J D Kriesel; J S Dumler; L E Wagoner; E D Wright; S L Spruance
Journal:  West J Med       Date:  1993-06

Review 4.  Q fever.

Authors:  M Maurin; D Raoult
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

5.  Humoral immune response to Q fever: enzyme-linked immunosorbent assay antibody response to Coxiella burnetii in experimentally infected guinea pigs.

Authors:  J C Williams; L A Thomas; M G Peacock
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Characterization of a phase I Coxiella burnetii chloroform-methanol residue vaccine that induces active immunity against Q fever in C57BL/10 ScN mice.

Authors:  J C Williams; T A Damrow; D M Waag; K Amano
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

7.  Reduced immune responsiveness and lymphoid depletion in mice infected with Ehrlichia risticii.

Authors:  Y Rikihisa; G C Johnson; C J Burger
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

8.  Chloroform-Methanol Residue of Coxiella burnetii Markedly Potentiated the Specific Immunoprotection Elicited by a Recombinant Protein Fragment rOmpB-4 Derived from Outer Membrane Protein B of Rickettsia rickettsii in C3H/HeN Mice.

Authors:  Wenping Gong; Pengcheng Wang; Xiaolu Xiong; Jun Jiao; Xiaomei Yang; Bohai Wen
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.